Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)



Status:Recruiting
Conditions:Colorectal Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:6/30/2016
Start Date:August 2015
End Date:May 2017
Contact:Toll Free Number
Phone:1-888-577-8839

Use our guide to learn which trials are right for you!

A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects With Previously Treated Locally Advanced Unresectable or Metastatic (Stage IV) Mismatched Repair Deficient or Microsatellite Instability-High Colorectal Carcinoma (KEYNOTE-164)

In this study, participants with previously-treated locally-advanced unresectable or
metastatic mismatched repair (MMR) deficient or microsatellite instability (MSI) high
colorectal carcinoma (CRC) will be treated with pembrolizumab (MK-3475, KEYTRUDA®)
monotherapy. There will be two cohorts in this study: Cohort A and Cohort B. For Cohort A,
participants are required to have been previously treated with standard therapies, which
must include fluoropyrimidine, oxaliplatin, and irinotecan. Enrollment into Cohort A has
been completed. For Cohort B, participants are required to have been previously treated with
at least one line of systemic standard of care therapy: fluoropyrimidine + oxaliplatin or
fluoropyrimidine + irinotecan +/ - anti-vascular endothelial growth factor (VEGF)/ epidermal
growth factor regulator (EGFR) monoclonal antibody.


Inclusion criteria:

- Histologically-proven locally advanced unresectable or metastatic high colorectal
carcinoma

- Locally confirmed MMR deficient or MSI status

- Have been previously treated with standard therapies, which must include, for Cohort
A, fluoropyrimidine, oxaliplatin, and irinotecan, and for Cohort B, at least one line
of systemic standard of care therapy: fluoropyrimidine + oxaliplatin or
fluoropyrimidine + irinotecan +/- anti-VEGF/EGFR monoclonal antibody

- Eastern Cooperative Oncology Group performance status of 0 or 1

- Life expectancy of greater than 3 months

- Provide an archival or newly obtained tumor tissue sample (Cohort B)

- At least one measureable lesion

- Female participants of childbearing potential should be willing to use 2 methods of
birth control or be surgically sterile, or abstain from heterosexual activity for the
course of the study through 120 days after the last dose of study medication

- Male participants should agree to use an adequate method of contraception starting
with the first dose of study therapy through 120 days after the last dose of study
medication

- Adequate organ function

Exclusion criteria:

- Currently participating in another study and receiving trial treatment, participated
in a study of an investigational agent and received trial treatment within 4 weeks of
the first dose of medication in this study, or used an investigational device within
4 weeks of the first dose of medication in this study

- Active autoimmune disease that has required systemic treatment in past 2 years

- Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form
of immunosuppressive therapy within 7 days prior to the first dose of study
medication

- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis

- Prior monoclonal antibody (mAb), chemotherapy, targeted small molecule therapy, or
radiation therapy within 2 weeks prior to study Day 1 or not recovered (i.e., ≤ Grade
1 or at baseline) from adverse events due to a previously administered agent

- Prior therapy with an anti-programmed cell death (PD)-1, anti-PD ligand 1
(anti-PD-L1), or anti-PD-L2 agent

- Known additional malignancy that is progressing or requires active treatment with the
exception of basal cell carcinoma of the skin or squamous cell carcinoma of the skin
that has undergone potentially curative therapy, or in situ cervical cancer

- Received a live vaccine within 30 days of planned start of study medication

- Known history of human immunodeficiency virus (HIV)

- Known active Hepatitis B or C

- Known history or any evidence of interstitial lung disease or active, non-infectious
pneumonitis

- Active infection requiring systemic therapy

- Known psychiatric or substance abuse disorders that would interfere with cooperation
with the requirements of the trial

- Pregnant or breastfeeding, or expecting to conceive or father children within the
projected duration of the trial, starting with the screening visit through 120 days
after the last dose of trial medication
We found this trial at
18
sites
?
mi
from
Stanford, CA
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Denver, CO
Click here to add this to my saved trials
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
?
mi
from
Louisville, KY
Click here to add this to my saved trials
?
mi
from
Monterey, CA
Click here to add this to my saved trials
North Ryde, 2113
Phone: 61 2 8988 8428
?
mi
from
North Ryde,
Click here to add this to my saved trials
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
?
mi
from
Portland, OR
Click here to add this to my saved trials
?
mi
from
Rochester, MN
Click here to add this to my saved trials
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
?
mi
from
Tyler, TX
Click here to add this to my saved trials
?
mi
from
Washington,
Click here to add this to my saved trials